156 related articles for article (PubMed ID: 36804411)
1. A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease.
Dagorn PG; Buchholz B; Kraus A; Batchuluun B; Bange H; Blockken L; Steinberg GR; Moller DE; Hallakou-Bozec S
Kidney Int; 2023 May; 103(5):917-929. PubMed ID: 36804411
[TBL] [Abstract][Full Text] [Related]
2. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
[TBL] [Abstract][Full Text] [Related]
3. Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease.
Leonhard WN; Song X; Kanhai AA; Iliuta IA; Bozovic A; Steinberg GR; Peters DJM; Pei Y
EBioMedicine; 2019 Sep; 47():436-445. PubMed ID: 31473186
[TBL] [Abstract][Full Text] [Related]
4. Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in vivo.
Cabrita I; Kraus A; Scholz JK; Skoczynski K; Schreiber R; Kunzelmann K; Buchholz B
Nat Commun; 2020 Aug; 11(1):4320. PubMed ID: 32859916
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-Dependent Kinase 1 Activity Is a Driver of Cyst Growth in Polycystic Kidney Disease.
Zhang C; Balbo B; Ma M; Zhao J; Tian X; Kluger Y; Somlo S
J Am Soc Nephrol; 2021 Jan; 32(1):41-51. PubMed ID: 33046531
[TBL] [Abstract][Full Text] [Related]
6. Ouabain enhances renal cyst growth in a slowly progressive mouse model of autosomal dominant polycystic kidney disease.
Trant J; Sanchez G; McDermott JP; Blanco G
Am J Physiol Renal Physiol; 2023 Dec; 325(6):F857-F869. PubMed ID: 37823195
[TBL] [Abstract][Full Text] [Related]
7. Aquaporin-3 deficiency slows cyst enlargement in experimental mouse models of autosomal dominant polycystic kidney disease.
Wang W; Geng X; Lei L; Jia Y; Li Y; Zhou H; Verkman AS; Yang B
FASEB J; 2019 May; 33(5):6185-6196. PubMed ID: 30768374
[TBL] [Abstract][Full Text] [Related]
8. Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency.
Chang MY; Ma TL; Hung CC; Tian YC; Chen YC; Yang CW; Cheng YC
Sci Rep; 2017 Aug; 7(1):7161. PubMed ID: 28769124
[TBL] [Abstract][Full Text] [Related]
9. Effects of Suramin on Polycystic Kidney Disease in a Mouse Model of Polycystin-1 Deficiency.
Chang MY; Hsu SH; Ma LY; Chou LF; Hung CC; Tian YC; Yang CW
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955634
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease.
Seeger-Nukpezah T; Proia DA; Egleston BL; Nikonova AS; Kent T; Cai KQ; Hensley HH; Ying W; Chimmanamada D; Serebriiskii IG; Golemis EA
Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12786-91. PubMed ID: 23858461
[TBL] [Abstract][Full Text] [Related]
11. Effect of celastrol on the progression of polycystic kidney disease in a Pkd1-deficient mouse model.
Chang MY; Hsieh CY; Lin CY; Chen TD; Yang HY; Chen KH; Hsu HH; Tian YC; Chen YC; Hung CC; Yang CW
Life Sci; 2018 Nov; 212():70-79. PubMed ID: 30268856
[TBL] [Abstract][Full Text] [Related]
12. The chloride channel CFTR is not required for cyst growth in an ADPKD mouse model.
Talbi K; Cabrita I; Kraus A; Hofmann S; Skoczynski K; Kunzelmann K; Buchholz B; Schreiber R
FASEB J; 2021 Oct; 35(10):e21897. PubMed ID: 34473378
[TBL] [Abstract][Full Text] [Related]
13. Functional TFEB activation characterizes multiple models of renal cystic disease and loss of polycystin-1.
Shillingford JM; Shayman JA
Am J Physiol Renal Physiol; 2023 Apr; 324(4):F404-F422. PubMed ID: 36794754
[TBL] [Abstract][Full Text] [Related]
14. cGAS Activation Accelerates the Progression of Autosomal Dominant Polycystic Kidney Disease.
Yoo M; Haydak JC; Azeloglu EU; Lee K; Gusella GL
J Am Soc Nephrol; 2024 Apr; 35(4):466-482. PubMed ID: 38247039
[TBL] [Abstract][Full Text] [Related]
15. Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD.
Leuenroth SJ; Bencivenga N; Chahboune H; Hyder F; Crews CM
Nephrol Dial Transplant; 2010 Jul; 25(7):2187-94. PubMed ID: 20139063
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
[TBL] [Abstract][Full Text] [Related]
17. A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector.
Yanda MK; Liu Q; Cebotaru L
J Biol Chem; 2018 Jul; 293(29):11513-11526. PubMed ID: 29875161
[TBL] [Abstract][Full Text] [Related]
18. Quercetin inhibits renal cyst growth in vitro and via parenteral injection in a polycystic kidney disease mouse model.
Zhu Y; Teng T; Wang H; Guo H; Du L; Yang B; Yin X; Sun Y
Food Funct; 2018 Jan; 9(1):389-396. PubMed ID: 29215110
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting Focal Adhesion Kinase Ameliorates Cyst Development in Polycystin-1-Deficient Polycystic Kidney Disease in Animal Model.
He J; Zhang S; Qiu Z; Li X; Huang H; Jin W; Xu Y; Shao G; Wang L; Meng J; Wang S; Geng X; Jia Y; Li M; Yang B; Jenny Lu HA; Zhou H
J Am Soc Nephrol; 2021 Sep; 32(9):2159-2174. PubMed ID: 34465607
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.
Jamadar A; Suma SM; Mathew S; Fields TA; Wallace DP; Calvet JP; Rao R
Cell Death Dis; 2021 Oct; 12(10):947. PubMed ID: 34650051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
